CA36118A1003 - Common Stock
FUSION PHARMACEUTICALS INC
NASDAQ:FUSN (5/7/2024, 7:00:00 PM)
After market: 21.4 0 (0%)21.4
-0.02 (-0.09%)
Fusion Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company is headquartered in Hamilton Ontario, Ontario and currently employs 102 full-time employees. The company went IPO on 2020-06-26. The firm is focused on developing radiopharmaceuticals as precision medicines. The company has developed its Targeted Alpha Therapies (TAT), platform to enable it to connect alpha particle emitting isotopes to various targeting molecules to selectively deliver the alpha particle payloads to tumors. The TAT platform is underpinned by its ability to radiolabel various classes of targeting molecules, its research and insights into the underlying chemistry and biology of alpha emitting radiopharmaceuticals, its differentiated capabilities in target identification, candidate generation, manufacturing and supply chain, its Fast-Clear linker technology used in conjunction with antibody-based targeting molecules, and development of imaging agents. Its clinical portfolio includes FPI-2265, FPI-1434 and FPI-2059. FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer in a Phase 2 trial.
FUSION PHARMACEUTICALS INC
270 Longwood Rd. S
Hamilton Ontario ONTARIO L8P 0A6
P: 12897990891
CEO: John Valliant
Employees: 102
Website: https://fusionpharma.com/
FUSN stock results show that Fusion Pharmaceuticals missed analyst estimates for earnings per share the first quarter of 2024.
/CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as precision...
/PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as...
/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law...
/PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjucates (RCs) as...
/CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjucates (RCs) as precision...
Here you can normally see the latest stock twits on FUSN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: